| Optimal management of type 2 diabetes: the evidence. | |
| | |
MedLine Citation:
|
PMID: 22118704 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
This paper reviews the evidence in relation to the optimal target for HbA1c and outlines a global treatment algorithm for people with type 2 diabetes. While most guidelines recommend a general HbA1c target of 7%, recent large scale intervention studies have examined the potential benefits of lower targets. These studies have generally shown that lower HbA1c targets provide no macrovascular benefits and limited effects on microvascular complications while increasing rates of hypoglycaemia. Overall these studies do not support a general HbA1c target lower than 7.0%. However an individual's HbA1c target should be set and reviewed taking into account treatment benefits, safety, and tolerability. This may mean that an HbA1c target lower than 7% is appropriate for some when it can be easily and safely achieved but equally a higher HbA1c target may be appropriate in others. Clinicians and consumers are fortunate in having a wide range of pharmacological agents available to treat hyperglycaemia, however access to many of these options is limited in many middle and low income countries. Developing treatment algorithms is complex for several reasons. The major limitation is the limited evidence base for choosing particular treatment options or combinations of medications. However it is possible to derive a generic evidence-informed consensus algorithm which considers availability, access and cost of medications which can be adapted for local country use. |
| | |
Authors:
|
S Colagiuri |
Related Documents
:
|
6397284 - Effects of diabetic control and biosynthetic human insulin on blood rheology in establi... 14709644 - Ifcc reference system for measurement of hemoglobin a1c in human blood and the national... 8954094 - Sites of glycation of beta b2-crystallin by glucose and fructose. 17078474 - Hereditary spherocytosis and other hemolytic anomalies distort diabetic control by glyc... 20195824 - Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the root... 1879304 - Management of newly diagnosed non-insulin-dependent (type 2) diabetes mellitus: a retro... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 14 Suppl 1 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-11-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 3-8 Citation Subset: IM |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
Boden Institute of Obesity, Nutrition and Exercise, The University of Sydney, Sydney, NSW 2066, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Probiotics in the management of gastrointestinal disease: Analysis of the attitudes and prescribing ...
Next Document: Treating diabetes today: a matter of selectivity of sulphonylureas.